Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lupus drug BMS-986326 enters human safety trials

NCT ID NCT06013995

Recruiting now Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 26 times

Summary

This study is testing a new medicine called BMS-986326 in 44 adults with discoid, subacute cutaneous, or systemic lupus. The main goal is to see if the drug is safe and how it behaves in the body after multiple doses given by IV or injection. Participants will be randomly assigned to receive the drug or a placebo, and researchers will monitor for side effects and measure drug levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Allen Arthritis

    WITHDRAWN

    Allen, Texas, 75013, United States

  • Arthritis Northwest, PLLC

    RECRUITING

    Spokane, Washington, 99204, United States

    Contact Phone: •••-•••-••••

  • Clinica Adventista Belgrano

    RECRUITING

    CABA, Buenos Aires F.D., 1430, Argentina

    Contact Phone: •••-•••-••••

  • Columbia University Irving Medical Center

    WITHDRAWN

    New York, New York, 10032, United States

  • Hospital Universitario Austral

    RECRUITING

    Pilar, Buenos Aires, 1629, Argentina

    Contact Phone: •••-•••-••••

  • Local Institution - 0005

    COMPLETED

    Duncansville, Pennsylvania, 16635, United States

  • Local Institution - 0029

    COMPLETED

    Tampa, Florida, 33606, United States

  • Local Institution - 0044

    COMPLETED

    Berlin, 10117, Germany

  • Local Institution - 0045

    COMPLETED

    Córdoba, Córdoba, 14004, Spain

  • Local Institution - 0046

    COMPLETED

    A Coruña, A Coruña [La Coruña], 15006, Spain

  • Local Institution - 0047

    COMPLETED

    Dresden, 01307, Germany

  • Local Institution - 0048

    COMPLETED

    San Diego, California, 92108, United States

  • Local Institution - 0051

    COMPLETED

    Leiden, 2333 CL, Netherlands

  • Local Institution - 0055

    COMPLETED

    Clearwater, Florida, 33765, United States

  • Local Institution - 0062

    COMPLETED

    Las Vegas, Nevada, 89102, United States

  • Local Institution - 0064

    ACTIVE_NOT_RECRUITING

    Cluj-Napoca, Cluj, 400006, Romania

  • Local Institution - 0065

    COMPLETED

    Bucharest, Bucharest, 11658, Romania

  • Local Institution - 0068

    WITHDRAWN

    Mexico City, DIF, 07760, Mexico

  • Local Institution - 0069

    COMPLETED

    Warsaw, 02-953, Poland

  • Local Institution - 0071

    COMPLETED

    Dessau, 06847, Germany

  • Local Institution - 0072

    ACTIVE_NOT_RECRUITING

    Sofia, 1618, Bulgaria

  • Local Institution - 0073

    WITHDRAWN

    Cuauhtémoc, Ciudad de México, DIF, 06100, Mexico

  • Local Institution - 0074

    ACTIVE_NOT_RECRUITING

    Poznan, 61-848, Poland

  • Local Institution - 0077

    WITHDRAWN

    Chihuahua City, 31217, Mexico

  • Metroplex Clinical Research Center

    WITHDRAWN

    Dallas, Texas, 75231, United States

  • North Georgia Rheumatology

    WITHDRAWN

    Lawrenceville, Georgia, 30046, United States

  • Skin Sciences

    RECRUITING

    Louisville, Kentucky, 40217, United States

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

LUPUS